Hemanext is developing a technology to enable the storage of RBC under anaerobic conditions. Removing O2 during storage removes the primary “fuel” for oxidative stress1-11. Previous published research has demonstrated that preventing oxidative damage can alleviate many of the signs associated with storage lesion development, including:
Hemanexts continues to invest significant resources in developing the technology and demonstrating both its effect on the characteristics of RBCs during storage, and eventually in clinical usage with patients.
To learn more about the storage lesions and its clinical consequences, click here.